+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 5Years - 15Years
All Genders
Healthy Volunteers
ID06103513

Comparison of Two Initial Doses of Growth Hormone Treatment in Children with Growth Hormone Deficiency During the First Year

Led by Northwell Health · Updated on 2026-10-21

50

Participants Needed

1

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are conducting a randomized, open-label study to compare two different starting doses of recombinant human growth hormone rhGH in children aged 5 to 15 years who have growth hormone deficiency. The study aims to evaluate safety, growth rate, and predicted adult height over the first year of treatment to find the optimal initial dose for this condition. Participants will be randomly assigned to one of two groups one group will receive rhGH at a dose of 0.3 mgkg per week, and the other group will receive 0.2 mgkg per week. Both doses will be given through subcutaneous injections nightly for 12 months. The study will monitor safety and growth outcomes at intervals throughout the year. During the study, participants will have assessments every 4 months to measure height velocity and predict adult height using bone age. Safety tests will include blood markers such as IGF1, IGFBP3, HbA1c, thyroid hormones, and others at baseline and follow-ups. The total participation spans one year, during which growth and safety parameters will be carefully tracked to understand the effects of the two dosing regimens.

CONDITIONS

Brief Title

Randomized Clinical Trial of Two Different Initial Growth Hormone Doses in Children

Research Team

N

Namma Pollack-Schreiber, MD

I

Ishrat Ghani

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here